CARB-X
Signal active
Investment Firm
Overview
Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre.
Highlights
Founded
2016
Industry
Employees
11-50
Investment
116
Lead Investment
108
Exits
29
Stages
N/A
Investor Type
Accelerator
Location
United States, North America
Contact Information
Social
Profile Resume
CARB-X, established in 2016 and headquartered in United States, North America., specializes in investments across Biotechnology, Health Care, Therapeutics, Education, Universities, Pharmaceutical, Medical, Medical Device, Business Development, Biometrics. The organization boasts a portfolio of 116 investments, with an average round size of $5.5M and 29 successful exits. Their recent investments include Cidara Therapeutics, University of Edinburgh, Redx Pharma, Spero Therapeutics, Entasis Therapeutics. The highest investment round they participated in was $6.5B. Among their most notable exits are Cidara Therapeutics and University of Edinburgh. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
CARB-X has made 116 investments. Their most recent investment was on Apr 30, 2024, when Vedanta Biosciences raised $3.9M.
CARB-X has made 10 diversity investments. Their most recent diversity investment was on Sep 01, 2022, when Avails Medical raised $1.7M.
investments
116
Diversity investments
10
Lead investments
108
Number of exits
29
Investments
116
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Mar 05, 2024 | Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) | Pharmaceutical | 1.1M |
| Apr 09, 2024 | Basilea Pharmaceutica | Biotechnology | 900.0K |
| Apr 22, 2024 | SNIPR Biome | Biotechnology | 5.5M |
| Apr 30, 2024 | Vedanta Biosciences | Biotechnology | 3.9M |
Basilea PharmaceuticaExits
29
Funding Timeline
Funding rounds
116
Investors
0
Funds
1
Funding Rounds
116
CARB-X has raised 116 rounds. Their latest funding was raised on Apr 30, 2024 from a Grant - Vedanta Biosciences round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Mar 05, 2024 | Grant - Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) | - | 1.1M | - |
| Apr 09, 2024 | Grant - Basilea Pharmaceutica | - | 900.0K | - |
| Apr 22, 2024 | Grant - SNIPR Biome | - | 5.5M | - |
| Apr 30, 2024 | Grant - Vedanta Biosciences | - | 3.9M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
N/A
Recent Activity
There is no recent news or activity for this profile.